Chinese Registry of rheumatoid arthritis (CREDIT): II. prevalence and risk factors of major comorbidities in Chinese patients with rheumatoid arthritis.
机构：[1]Department of Rheumatology, Peking Union Medical College Hospital,Peking Union Medical College and Chinese Academy of Medical Sciences,Key Laboratory of Rheumatology and Clinical Immunology, Ministry ofEducation, No .1 Shuaifuyuan, Wangfujing Ave, 100730 Beijing, China[2]Department of Rheumatology, Southwest Hospital, Third Military MedicalUniversity, Chongqing, China[3]Department of Rheumatology, The FirstPeople’s Hospital of Yunnan Province, Kunming, Yunnan, China[4]Departmentof Rheumatology, Jiujiang No .1 People’s Hospital, Jiujiang, Jiangxi, China[5]Department of Rheumatology, The Second Affiliated Hospital of NanchangUniversity, Nanchang, Jiangxi, China[6]Department of Rheumatology, WestChina Hospital, Sichuan University, Chengdu, Sichuan, China[7]Department ofRheumatology, The First Affiliated Hospital of Nanchang University,Nanchang, Jiangxi, China[8]Department of Rheumatology, The First AffiliatedHospital of Henan University of Science and Technology, Luoyang, Henan,China[9]Department of Rheumatology, The First Affiliated Hospital of BaotouMedical College, Inner Mongolia University of Science and Technology,Baotou, Inner Mongolia, China[10]Department of Rheumatology, The FirstHospital of Jilin University, Changchun, Jilin, China[11]Department ofEpidemiology and Bio-statistics, Institute of Basic Medical Sciences, ChineseAcademy of Medical Sciences, School of Basic Medicine, Peking UnionMedical College, Beijing, China
Rheumatoid arthritis patients are at higher risk of developing comorbidities. The main objective of this study was to evaluate the prevalence of major comorbidities in Chinese rheumatoid arthritis patients. We also aimed to identify factors associated with these comorbidities.
Baseline demographic, clinical characteristics and comorbidity data from RA patients enrolled in the Chinese Registry of rhEumatoiD arthrITis (CREDIT) from Nov 2016 to August 2017 were presented and compared with those from five other registries across the world. Possible factors related to three major comorbidities (cardiovascular disease, fragility fracture and malignancy) were identified using multivariate logistic regression analyses.
A total of 13,210 RA patients were included (80.6% female, mean age 52.9 years and median RA duration 4.0 years). Baseline prevalence rates of major comorbidities were calculated: CVD, 2.2% (95% CI 2.0-2.5%); fragility fracture, 1.7% (95% CI 1.5-1.9%); malignancy, 0.6% (95% CI 0.5-0.7%); overall major comorbidities, 4.2% (95% CI 3.9-4.6%). Advanced age was associated with all comorbidities. Male gender and disease duration were positively related to CVD. Female sex and longer disease duration were potential risk factors for fragility fractures. Ever use of methotrexate (MTX) was negatively related to baseline comorbidities.
Patients with rheumatoid arthritis in China have similar prevalence of comorbidities with other Asian countries. Advanced age and long disease duration are possible risk factors for comorbidities. On the contrary, MTX may protect RA patients from several major comorbidities, supporting its central role in the management of rheumatoid arthritis.
基金：
the Chinese National Key Technology R&D Program (2017YFC0907601, 2017YFC0907604).
第一作者机构：[1]Department of Rheumatology, Peking Union Medical College Hospital,Peking Union Medical College and Chinese Academy of Medical Sciences,Key Laboratory of Rheumatology and Clinical Immunology, Ministry ofEducation, No .1 Shuaifuyuan, Wangfujing Ave, 100730 Beijing, China
共同第一作者：
通讯作者：
推荐引用方式(GB/T 7714)：
Jin Shangyi,Li Mengtao,Fang Yongfei,et al.Chinese Registry of rheumatoid arthritis (CREDIT): II. prevalence and risk factors of major comorbidities in Chinese patients with rheumatoid arthritis.[J].ARTHRITIS RESEARCH & THERAPY.2017,19:doi:10.1186/s13075-017-1457-z.
APA：
Jin Shangyi,Li Mengtao,Fang Yongfei,Li Qin,Liu Ju...&Zeng Xiaofeng.(2017).Chinese Registry of rheumatoid arthritis (CREDIT): II. prevalence and risk factors of major comorbidities in Chinese patients with rheumatoid arthritis..ARTHRITIS RESEARCH & THERAPY,19,
MLA：
Jin Shangyi,et al."Chinese Registry of rheumatoid arthritis (CREDIT): II. prevalence and risk factors of major comorbidities in Chinese patients with rheumatoid arthritis.".ARTHRITIS RESEARCH & THERAPY 19.(2017)
医学